Efficacy Add Safety Of Peritoneal Perfusion Chemotherapy Combined With Intravenous Chemotherapy After Radical Gastrectomy For Advanced Gastric Cancer

Objective: To explore the efficacy and safety of early chemotherapy by hyperthermic intraperitoneal chemotherapy(HIPEC)combined with intravenous chemotherapy(FOLFOX)after radical resection of advanced gastric cancer.Methods: A total of 68 patients undergoing radical resection of advanced gastric cancer in our department(T staging of the selected cases was T3 and T4,and clinical staging was stage II and III)were divided into observation group and control group according to the order of admission,with 34 patients in each group.Patients in the observation group received peritoneal perfusion chemotherapy combined with systemic intravenous chemotherapy after radical gastrectomy,while patients in the control group received only systemic intravenous chemotherapy after surgery.Postoperative complications,T lymphocyte subsets,adverse reactions to intravenous chemotherapy,and 1,2,and 3-year recurrence rates and survival rates were compared between the two groups.Results: All enrolled patients successfully completed treatment and follow-up.The incidence of postoperative abdominal pain and abdominal distension in the observation group was higher than that in the control group(P<0.05),but they were all temporary.The symptoms of the patients could be relieved by themselves or relieved after symptomatic treatment,and there was no statistical difference in other adverse reactions(P>0.05).The recovery rate of T lymphocyte subsets in the observation group was faster than that in the control group(P<0.05).The 2-year and 3-year recurrence rate in the control group was higher than that in the observation group,and the survival rate was lower than that in the observation group(P<0.05).There was no statistical difference in 1-year recurrence rate and survival rate between the two groups(P>0.05).Conclusion: Early peritoneal peritoneal perfusion chemotherapy combined with intravenous chemotherapy after radical resection of advanced gastric cancer can contribute to the recovery of cellular immune function,reduce the recurrence rate of patients,improve the long-term survival rate of patients,and do not increase the obvious adverse reactions,which can be promoted in clinical practice.